Physician profile
Christopher Brune
NPI 1679930648
$4,919.44
in general payments reported to CMS, 2019-2025
24 companies · $893 in 2025
The $893 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $338 · 2022: $707 · 2023: $1,482 · 2024: $1,499 · 2025: $893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,789 · Education: $85.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,789.04 |
| Education | $85.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,028.18 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $886.39 | 2021-2024 | Dupixent, Libtayo |
| Genzyme Corporation | $638.28 | 2021-2025 | |
| Galderma Laboratories, L.P. | $439.51 | 2021-2025 | Aklief, Nemluvio, Oracea |
| Pfizer INC. | $239.87 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $206.53 | 2024-2025 | |
| Incyte Corporation | $196.55 | 2021-2025 | Opzelura |
| Ucb, INC. | $171.93 | 2024-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $166.38 | 2021-2024 | Jublia |
| Janssen Biotech, INC. | $164.05 | 2021-2025 | Tremfya |
| Amgen INC. | $162.11 | 2021-2025 | Otezla, Otezla, Enbrel |
| Leo Pharma INC. | $127.58 | 2022-2025 | Adbry |
| Dermavant Sciences, INC. | $107.37 | 2023-2024 | Vtama |
| Lilly USA, LLC | $66.82 | 2021-2024 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $62.06 | 2022-2024 | Sotyktu |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $54.68 | 2025 | Vtama |
| Organogenesis INC. | $43.42 | 2024-2025 | Cygnus Dual |
| Verrica Pharmaceuticals INC. | $29.72 | 2023 | Ycanth |
| Arcutis Biotherapeutics, INC. | $28.38 | 2023-2024 | Zoryve |
| Sun Pharmaceutical Industries INC. | $27.27 | 2023 | Ilumya, Winlevi |
| Genentech USA, INC. | $22.76 | 2022 | |
| Bioventus LLC | $19.54 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.17 | 2023 | Spevigo |
| Almirall LLC | $11.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Brune listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.